Literature DB >> 29582366

The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism.

Gui-Wei Liu1, Yan-Hua Liu2, Guo-Sheng Jiang2, Wei-Dan Ren2.   

Abstract

Recent studies hint that Ginsenoside is involved in cancer prevention and treatment. In this study, we investigated the effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma (CRC) cells and its mechanism. The resistance reversion effect of Ginsenoside Rh2 in CRC cells was analyzed using CCK-8 assay. After treating with Ginsenoside Rh2, the cell cycle distribution and cellular apoptosis were analyzed by flow cytometry, cell migration was determined by transwell migration assay, the expression of drug-resistance genes and proteins were evaluated using quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot, respectively. Ginsenoside Rh2 could enhance the cytotoxicity of 5-FU in drug-resistant CRC cells (LoVo/5-FU and HCT-8/5-FU). Treatment with Ginsenoside Rh2 could result in an increase of cell numbers in G0/G1 phase accompanied with a decrease in S-phase, and induced cellular apoptosis in drug-resistant CRC cells. In addition, the migration process and EMT process of drug-resistant CRC cells were suppressed by treatment of Ginsenoside Rh2. Compared to control group, expression of drug-resistance genes, such as MRP1, MDR1, LRP and GST, were negatively correlated to Ginsenoside Rh2. All these results indicated that Ginsenoside Rh2 could effectively reverse drug resistance in human colorectal carcinoma cell and its mechanism involved the prevention of cellular proliferation and migration, the promotion of cellular apoptosis and the alteration of drug-resistance genes, which suggested that Ginsenoside Rh2 may act as a promising candidate for drug resistance in human colorectal carcinoma chemotherapy.

Entities:  

Keywords:  Drug resistance; Ginsenoside Rh2; Human colorectal carcinoma

Mesh:

Substances:

Year:  2018        PMID: 29582366     DOI: 10.1007/s13577-017-0189-3

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  37 in total

1.  A dynamic study on reversal of multidrug resistance by ginsenoside Rh₂ in adriamycin-resistant human breast cancer MCF-7 cells.

Authors:  Bei Zhou; Xiuli Xiao; Lili Xu; Lian Zhu; Liang Tan; Hao Tang; Youyu Zhang; Qingji Xie; Shouzhuo Yao
Journal:  Talanta       Date:  2011-11-02       Impact factor: 6.057

2.  MicroRNA-195 inhibits proliferation of cervical cancer cells by targeting cyclin D1a.

Authors:  Ning Wang; Heng Wei; Duo Yin; Yanming Lu; Yao Zhang; Qiao Zhang; Xiaoxin Ma; Shulan Zhang
Journal:  Tumour Biol       Date:  2015-10-28

3.  Interchangeable Roles for E2F Transcriptional Repression by the Retinoblastoma Protein and p27KIP1-Cyclin-Dependent Kinase Regulation in Cell Cycle Control and Tumor Suppression.

Authors:  Michael J Thwaites; Matthew J Cecchini; Daniel T Passos; Ian Welch; Frederick A Dick
Journal:  Mol Cell Biol       Date:  2017-01-04       Impact factor: 4.272

4.  Gene and protein expression in the oxaliplatin-resistant HT29/L-OHP human colon cancer cell line.

Authors:  Z Xiang; Q J Kang; X Xiang
Journal:  Genet Mol Res       Date:  2015-09-21

Review 5.  Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.

Authors:  Elena De Mattia; Erika Cecchin; Giuseppe Toffoli
Journal:  Drug Resist Updat       Date:  2015-05-22       Impact factor: 18.500

6.  Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting p50/p65 NF-κB Pathway in Colorectal Cancer.

Authors:  Hua Sui; Li-Hong Zhou; Ya-Li Zhang; Jian-Ping Huang; Xuan Liu; Qing Ji; Xiao-Ling Fu; Hao-Tian Wen; Zhe-Sheng Chen; Wan-Li Deng; Hui-Rong Zhu; Qi Li
Journal:  J Cell Biochem       Date:  2016-02-29       Impact factor: 4.429

7.  The antitumor activity study of ginsenosides and metabolites in lung cancer cell.

Authors:  Feng-Yuan Xu; Wen-Qing Shang; Jia-Jun Yu; Qian Sun; Ming-Qing Li; Jian-Song Sun
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Ginseng consumption and risk of cancer: A meta-analysis.

Authors:  Xin Jin; Dao-Biao Che; Zhen-Hai Zhang; Hong-Mei Yan; Zeng-Yong Jia; Xiao-Bin Jia
Journal:  J Ginseng Res       Date:  2015-09-02       Impact factor: 6.060

10.  Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.

Authors:  Wendian Zhang; Hechao Zhou; Ying Yu; Jingjing Li; Haiwen Li; Danxian Jiang; Zihong Chen; Donghong Yang; Zumin Xu; Zhonghua Yu
Journal:  Onco Targets Ther       Date:  2016-06-02       Impact factor: 4.147

View more
  7 in total

1.  c-MYC-mediated TRIB3/P62+ aggresomes accumulation triggers paraptosis upon the combination of everolimus and ginsenoside Rh2.

Authors:  Min-Xia Su; Yu-Lian Xu; Xiao-Ming Jiang; Mu-Yang Huang; Le-Le Zhang; Luo-Wei Yuan; Xiao-Huang Xu; Qi Zhu; Jian-Li Gao; Jia-Hong Lu; Xiuping Chen; Ming-Qing Huang; Yitao Wang; Jin-Jian Lu
Journal:  Acta Pharm Sin B       Date:  2021-09-22       Impact factor: 14.903

2.  20 (S)-ginsenoside Rh2 inhibits colorectal cancer cell growth by suppressing the Axl signaling pathway in vitro and in vivo.

Authors:  Haibo Zhang; Jun-Koo Yi; Hai Huang; Sijun Park; Wookbong Kwon; Eungyung Kim; Soyoung Jang; Si-Yong Kim; Seong-Kyoon Choi; Duhak Yoon; Sung-Hyun Kim; Kangdong Liu; Zigang Dong; Zae Young Ryoo; Myoung Ok Kim
Journal:  J Ginseng Res       Date:  2021-07-12       Impact factor: 5.735

Review 3.  Combating Drug Resistance in Colorectal Cancer Using Herbal Medicines.

Authors:  Ga-Young Lee; Jin-Seok Lee; Chang-Gue Son; Nam-Hun Lee
Journal:  Chin J Integr Med       Date:  2020-08-01       Impact factor: 1.978

4.  Oxymatrine Synergistically Enhances Doxorubicin Anticancer Effects in Colorectal Cancer.

Authors:  Di Pan; Wen Zhang; Nenling Zhang; Yini Xu; Yi Chen; Jianqing Peng; Yan Chen; Yanyan Zhang; Xiangchun Shen
Journal:  Front Pharmacol       Date:  2021-06-30       Impact factor: 5.810

Review 5.  Emerging Significance of Ginsenosides as Potentially Reversal Agents of Chemoresistance in Cancer Therapy.

Authors:  Jin-Feng Xu; Yan Wan; Fei Tang; Lu Chen; Yu Yang; Jia Xia; Jiao-Jiao Wu; Hui Ao; Cheng Peng
Journal:  Front Pharmacol       Date:  2021-12-17       Impact factor: 5.810

Review 6.  Ginsenosides emerging as both bifunctional drugs and nanocarriers for enhanced antitumor therapies.

Authors:  Hong Wang; Yu Zheng; Qiang Sun; Zhen Zhang; Mengnan Zhao; Cheng Peng; Sanjun Shi
Journal:  J Nanobiotechnology       Date:  2021-10-15       Impact factor: 10.435

7.  Systems Pharmacology and Verification of ShenFuHuang Formula in Zebrafish Model Reveal Multi-Scale Treatment Strategy for Septic Syndrome in COVID-19.

Authors:  Tengwen Liu; Yuhong Guo; Jingxia Zhao; Shasha He; Yunjing Bai; Ning Wang; Yan Lin; Qingquan Liu; Xiaolong Xu
Journal:  Front Pharmacol       Date:  2020-09-15       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.